COVID-19, colchicine and glycemia.
作者信息
Ilias Ioannis, Milionis Charalambos
机构信息
Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, Athens GR-11521, Greece.
Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, Athens GR-11521, Greece.
出版信息
Med Hypotheses. 2021 Apr;149:110547. doi: 10.1016/j.mehy.2021.110547. Epub 2021 Feb 18.
Abstract
摘要
相似文献
1
COVID-19, colchicine and glycemia.新型冠状病毒肺炎、秋水仙碱与血糖
Med Hypotheses. 2021 Apr;149:110547. doi: 10.1016/j.mehy.2021.110547. Epub 2021 Feb 18.
2
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.秋水仙碱对比标准治疗对 COVID-19 住院患者心脏和炎症生物标志物及临床结局的影响：GRECCO-19 随机临床试验。
JAMA Netw Open. 2020 Jun 1;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
3
Pro: Tight control of blood glucose in the brain-injured patient is important and desirable.赞成观点：对脑损伤患者进行严格的血糖控制很重要且值得追求。
J Neurosurg Anesthesiol. 2009 Jan;21(1):52-4. doi: 10.1097/01.ana.0000343199.62838.02.
4
[Management of glycemia: an audit in 66 ICUs].[血糖管理：66个重症监护病房的一项审计]
Ann Fr Anesth Reanim. 2013 Feb;32(2):84-8. doi: 10.1016/j.annfar.2012.12.002. Epub 2013 Jan 18.
5
Can we still consider treatment with colchicine effective in SARS-COV-2 infection? Systematic review, meta-analysis, and trial sequential analysis.我们还能认为柳氮磺胺吡啶治疗 SARS-CoV-2 感染有效吗？系统评价、荟萃分析和试验序贯分析。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7151-7161. doi: 10.26355/eurrev_202111_27269.
6
Clinical need for continuous glucose monitoring in the hospital.医院中持续血糖监测的临床需求。
J Diabetes Sci Technol. 2009 Nov 1;3(6):1309-18. doi: 10.1177/193229680900300611.
7
Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.托珠单抗和秋水仙碱在 COVID-19 相关凝血障碍中的不同影响：α-防御素的作用。
Br J Haematol. 2022 Feb;196(4):923-927. doi: 10.1111/bjh.17885. Epub 2021 Oct 27.
8
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.秋水仙碱联合常规治疗与单纯常规治疗对 COVID-19 住院患者插管和 28 天死亡率的影响：一项随机临床试验。
JAMA Netw Open. 2021 Dec 1;4(12):e2141328. doi: 10.1001/jamanetworkopen.2021.41328.
9
Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial.短程秋水仙碱治疗中重度 COVID-19 肺炎和炎症过高患者的疗效：一项随机临床试验。
Sci Rep. 2022 Jun 2;12(1):9208. doi: 10.1038/s41598-022-13424-6.
10
The prognostic role of hyperglycemia and glucose variability in covid-related acute respiratory distress Syndrome.高血糖和血糖变异性在新冠相关急性呼吸窘迫综合征中的预后作用。
Diabetes Res Clin Pract. 2021 May;175:108789. doi: 10.1016/j.diabres.2021.108789. Epub 2021 Apr 1.
引用本文的文献
1
Investigation and Causes of Spontaneous (Non-Diabetic) Hypoglycaemia in Adults: Pitfalls to Avoid.成人自发性（非糖尿病性）低血糖症的调查与病因：需避免的陷阱
Diagnostics (Basel). 2023 Oct 22;13(20):3275. doi: 10.3390/diagnostics13203275.
本文引用的文献
1
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial.秋水仙碱治疗中重度 COVID-19 的有益作用：一项随机、双盲、安慰剂对照临床试验。
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001455.
2
Glycemia, Beta-Cell Function and Sensitivity to Insulin in Mildly to Critically Ill Covid-19 Patients.轻度至危重新冠肺炎患者的血糖、β细胞功能和胰岛素敏感性。
Medicina (Kaunas). 2021 Jan 14;57(1):68. doi: 10.3390/medicina57010068.
3
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.痛风的心血管疾病药物治疗：药物疗效和预后的综述。
Am J Cardiovasc Drugs. 2021 Sep;21(5):499-512. doi: 10.1007/s40256-020-00459-1. Epub 2020 Dec 28.
4
Clinical Study of Hyperglycemia and SARS-CoV-2 Infection in Intensive Care Unit Patients.《重症监护病房患者高血糖与 SARS-CoV-2 感染的临床研究》
In Vivo. 2020 Sep-Oct;34(5):3029-3032. doi: 10.21873/invivo.12136.
5
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.秋水仙碱对比标准治疗对 COVID-19 住院患者心脏和炎症生物标志物及临床结局的影响：GRECCO-19 随机临床试验。
JAMA Netw Open. 2020 Jun 1;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
6
Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?COVID-19 影响下的高血糖患者结局：我们能否在血糖控制方面做得更好？
Diabetes Care. 2020 Jul;43(7):1408-1415. doi: 10.2337/dc20-0723. Epub 2020 May 19.
7
Hyperglycemia and the novel Covid-19 infection: Possible pathophysiologic mechanisms.高血糖与新型冠状病毒肺炎感染：可能的病理生理机制
Med Hypotheses. 2020 Jun;139:109699. doi: 10.1016/j.mehy.2020.109699. Epub 2020 Mar 26.
8
Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout.退伍军人事务部痛风患者中，秋水仙碱与糖尿病风险之间的关联。
Clin Ther. 2015 Jun 1;37(6):1206-15. doi: 10.1016/j.clinthera.2015.03.010. Epub 2015 Apr 7.
9
Colchicine and insulin secretion in man.秋水仙碱与人体胰岛素分泌
Diabetes. 1981 Dec;30(12):1008-12. doi: 10.2337/diab.30.12.1008.
Zotero 插件